• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
IL-5 Signaling Pathway in Oncology Drug Pipeline Update 2014 Product Image

IL-5 Signaling Pathway in Oncology Drug Pipeline Update 2014

  • ID: 1537333
  • October 2014
  • Region: Global
  • Bioseeker

The IL-5 singaling pathway activates the JAK/STAT and Raf/MAPK signaling modules.
There are today 123 companies plus partners developing 169 IL-5 pathway targeting drugs in 719 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 70 drugs. Il-5 Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 142 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 139 out of the 141 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 31 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

How May Drug Pipeline Update Be of Use?
- Show investors/board/management that you are right on top of drug development READ MORE >

Delivery Format: Desktop App plus Online Access to Updates (One Year)

Note: Product cover images may vary from those shown


Our Clients

Our clients' logos